ArticleCancer cell2026
Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.
Abstract read
In one paragraph
Article in Cancer cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Regulatory T cells in breast cancer drivers of immune suppression and targets for immunotherapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Triet Minh BuiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Ernesto Rojas JimenezDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Zheqi LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Pierre FoidartDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Julieann PuleoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Pengze YanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Aashna JhaveriDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.
Lin YangDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.
Jun NishidaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Marco SeehawerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Xinran CaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Kimberly Ann ParkerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Xiaodi QinDuke Cancer Institute, Duke University School of Medicine, Durham, NC 27705, USA.
Oyku Ece SumerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Xiao-Yun HuangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Ashka PatelDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Deborah DillonDepartment of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Charles H McDonnellSutter Institute for Medical Research, Roseville, CA 95661, USA.
Ron RowberrySutter Institute for Medical Research, Roseville, CA 95661, USA.
Shinedeep JhajjSutter Institute for Medical Research, Roseville, CA 95661, USA.
Catherine BakerSutter Institute for Medical Research, Roseville, CA 95661, USA.
Daniel D BrownInstitute for Precision Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Siri H StrandDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jeffrey R MarksDepartment of Surgery, Duke University School of Medicine, Durham, NC 27708, USA.
Graham A ColditzDepartment of Surgery, Washington University School of Medicine, St. Louis, MO 63108, USA.
So Yeon ParkDepartment of Pathology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Republic of Korea.
Adrian V LeeInstitute for Precision Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA; UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
Michael AngeloDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Priscilla F McAuliffeUPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
Kristie BobolisSutter Institute for Medical Research, Roseville, CA 95661, USA.
Robert WestDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Glenn DranoffDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
E Shelley HwangDepartment of Surgery, Duke University School of Medicine, Durham, NC 27708, USA.
Simona CristeaDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.
Kornelia PolyakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. Electronic address: kornelia_polyak@dfci.harvard.edu.
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0MTissue and Pathology CoreP50CA168504 · NCI · DANA-FARBER CANCER INST · PI LEIF W ELLISEN, NANCY U LIN · 2013 to 2026
$30.1MTargeting intratumor heterogeneity in breast cancerR35CA197623 · NCI · DANA-FARBER CANCER INST · PI KORNELIA POLYAK · 2015 to 2026
$12.4MCancer Chemical Biology and Metabolism Training ProgramT32CA236754 · NCI · DANA-FARBER CANCER INST · PI Nika N Danial, THOMAS M ROBERTS · 2019 to 2026
$2.6MHigh-Throughput DNA Sequencing SystemS10OD036228 · OD · DANA-FARBER CANCER INST · PI HERBERT, ZACHARY T · 2024 to 2024
$1.0MElucidating the role of RNA splicing in the metastatic seeding and outgrowth of aggressive cancers.K00CA274597 · NCI · DANA-FARBER CANCER INST · PI Kimberly Parker · 2024 to 2026
$296kElucidating the role of RNA splicing in the metastatic seeding and outgrowth of aggressive cancers.F99CA274597 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI PARKER, KIMBERLY · 2022 to 2023
$87kNCI NIH HHS F99 CA274597NCI NIH HHS K00 CA274597NCI NIH HHS P30 CA047904NCI NIH HHS P50 CA168504NCI NIH HHS R35 CA197623NCI NIH HHS T32 CA236754NIH HHS S10 OD036228
Abstract
Immune escape during the ductal carcinoma in situ (DCIS)-to-invasive breast cancer (IBC) transition shapes tumor evolution. Through transcriptomic mapping of the immune landscapes of normal breast, DCIS, and IBC from large patient cohorts, we identified T and myeloid cells as the primary distinguishing features between DCIS and IBC. We discovered cycling regulatory T cells (cycTreg) as an orchestrator of immunosuppression in IBC. cycTreg frequency predicts cytotoxic CD8
Indexed as
Breast NeoplasmsCarcinoma, Intraductal, NoninfiltratingT-Lymphocytes, RegulatoryTumor EscapeAnimalsDisease ProgressionFemaleHumansRatsdendritic cellsductal carcinoma in situimmune escapeimmuno-oncologyprogenitor T cellsregulatory T cellssingle-cell transcriptomic atlas
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.